Alphatec (ATEC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Q4 2025 revenue reached $213 million, representing a 20% year-over-year growth and a $36 million increase [3][6] - Full year 2025 revenue totaled $764 million, a $153 million increase year-over-year, equating to a 25% growth [4][16] - Adjusted EBITDA for Q4 was $33 million, reflecting a 61% year-over-year increase, with a margin of 16% [15][22] - Full year Adjusted EBITDA was $93 million, approximately 12% of sales, marking a $63 million improvement year-over-year [17][22] Business Line Data and Key Metrics Changes - Surgical revenue in Q4 was $190 million, up 21% year-over-year, while EOS revenue was $23 million, up 14% [6][7] - For the full year, surgical revenue was $687 million, a 26% increase, driven by a 22% growth in procedural volume [16][17] - EOS revenue for the full year was $77 million, reflecting a 15% year-over-year growth [16] Market Data and Key Metrics Changes - U.S. revenue per case increased by 1.4%, with lateral and cervical procedures both up 6% [6][7] - Same-store sales in the U.S. grew 20% year-over-year, indicating strong growth in established territories [7] - International business presented a 120 basis point headwind due to lower average revenue per case [7] Company Strategy and Development Direction - The company is focused on creating clinical distinction through proceduralization, particularly in lateral surgery, which is seen as a growth engine [24][26] - ATEC is expanding its sales force and enhancing its product offerings, including the introduction of advanced technologies like Valence and EOS Insight [25][28] - The company aims to leverage its unique procedural ecosystem to capture a larger market share in both established and untapped markets [26][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of top-line growth, driven by increasing surgeon adoption and procedural volume [7][19] - The outlook for 2026 anticipates a revenue growth of 17% to approximately $890 million, with an Adjusted EBITDA guidance of $134 million [19][22] - The company is positioned for long-term profitable growth, emphasizing the importance of innovation and operational discipline [34] Other Important Information - The company ended Q4 with $161 million in cash and had access to an additional $60 million in undrawn credit [18] - Positive free cash flow of $8 million in Q4 marked the first full year of positive free cash flow for the company [18][19] Q&A Session Summary Question: Clarification on Q4 results and 2026 guidance - The revenue and EBITDA figures for Q4 were in line with expectations, with EBITDA exceeding consensus by 10% [37][39] Question: Seasonal patterns for 2026 - The company expects increased seasonality in Q2 and Q3, with Q1 revenue anticipated to be around 22.1% of total sales [40][41] Question: Attracting sales talent - The company is experiencing strong demand for its portfolio, indicating it remains a preferred destination for sales talent [46]